FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892187204> ?p ?o ?g. }

• W2892187204 abstract "e20654 Background: Although most NSCLC patients with sensitizing EGFR mutations (L858R, Exon 19 deletion) have an impressive initial response, the vast majority develop acquired resistance after 9-14 months of EGFR TKI therapy. Clearly, more effective strategies to prevent resistance emergence are needed. We recently reported a randomized phase 2 trial that showed that LCT with surgery or radiation, for molecularly unselected patients with oligometastatic NSCLC who did not progress after initial systemic therapy, improved progression-free survival (PFS) compared to maintenance therapy alone (Gomez, et al., 2016). Herein, we aim to determine the outcomes of LCT after first line TKI in patients with metastatic EGFR mutant NSCLC. Methods: This is a post-hoc analysis of our recently published phase 2 clinical trial and a retrospective review of MD Anderson Cancer Center GEMINI database. Eligible patients had metastatic EGFR mutant NSCLC, had first line TKI without progression followed by LCT with surgery or radiation. Results:In GEMINI database, 129 EGFR (L858R/Exon 19 deletion) mutant NSCLC patients were treated with first line TKI (erlotinib, gefitinib or afatinib) and 12 were treated with TKI followed by LCT (3 treated within our published clinical trial and 9 at the discretion of their physician). Among the 12 patients treated with TKI plus LCT, 8 patients had oligometastatic disease (defined as ≤3 metastases) and 4 patients had > 3 metastases. LCT regimens were hypofractionated radiotherapy or stereotactic ablative body radiotherapy for 11 patients and surgery for one patient. Patients treated with TKI followed by LCT had a significantly longer PFS (36 months) compared to patients treated with first line TKI alone (PFS 14 months, p = 0.0024, log-rank). Conclusions:Our retrospective data suggests that first line TKI plus LCT is a promising therapeutic strategy that led to a significant outcome improvement for patients with EGFR mutant NSCLC. A multicenter phase 2 clinical trial comparing TKI plus LCT to TKI alone is planned." @default.
• W2892187204 created "2018-09-27" @default.
• W2892187204 creator A5008790176 @default.
• W2892187204 creator A5022433974 @default.
• W2892187204 creator A5023516148 @default.
• W2892187204 creator A5025095617 @default.
• W2892187204 creator A5027152610 @default.
• W2892187204 creator A5029399672 @default.
• W2892187204 creator A5037889591 @default.
• W2892187204 creator A5048380048 @default.
• W2892187204 creator A5055965589 @default.
• W2892187204 creator A5056267838 @default.
• W2892187204 creator A5060262778 @default.
• W2892187204 creator A5072939839 @default.
• W2892187204 creator A5076621000 @default.
• W2892187204 date "2017-05-20" @default.
• W2892187204 modified "2023-09-22" @default.
• W2892187204 title "Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small cell lung cancer (NSCLC)." @default.
• W2892187204 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e20654" @default.
• W2892187204 hasPublicationYear "2017" @default.
• W2892187204 type Work @default.
• W2892187204 sameAs 2892187204 @default.
• W2892187204 citedByCount "0" @default.
• W2892187204 crossrefType "journal-article" @default.
• W2892187204 hasAuthorship W2892187204A5008790176 @default.
• W2892187204 hasAuthorship W2892187204A5022433974 @default.
• W2892187204 hasAuthorship W2892187204A5023516148 @default.
• W2892187204 hasAuthorship W2892187204A5025095617 @default.
• W2892187204 hasAuthorship W2892187204A5027152610 @default.
• W2892187204 hasAuthorship W2892187204A5029399672 @default.
• W2892187204 hasAuthorship W2892187204A5037889591 @default.
• W2892187204 hasAuthorship W2892187204A5048380048 @default.
• W2892187204 hasAuthorship W2892187204A5055965589 @default.
• W2892187204 hasAuthorship W2892187204A5056267838 @default.
• W2892187204 hasAuthorship W2892187204A5060262778 @default.
• W2892187204 hasAuthorship W2892187204A5072939839 @default.
• W2892187204 hasAuthorship W2892187204A5076621000 @default.
• W2892187204 hasConcept C104317684 @default.
• W2892187204 hasConcept C121608353 @default.
• W2892187204 hasConcept C126322002 @default.
• W2892187204 hasConcept C143065580 @default.
• W2892187204 hasConcept C143998085 @default.
• W2892187204 hasConcept C170493617 @default.
• W2892187204 hasConcept C185592680 @default.
• W2892187204 hasConcept C2776256026 @default.
• W2892187204 hasConcept C2778087573 @default.
• W2892187204 hasConcept C2778820342 @default.
• W2892187204 hasConcept C2779177807 @default.
• W2892187204 hasConcept C2779438470 @default.
• W2892187204 hasConcept C2780580887 @default.
• W2892187204 hasConcept C2781230642 @default.
• W2892187204 hasConcept C42362537 @default.
• W2892187204 hasConcept C502942594 @default.
• W2892187204 hasConcept C55493867 @default.
• W2892187204 hasConcept C71924100 @default.
• W2892187204 hasConcept C81729549 @default.
• W2892187204 hasConceptScore W2892187204C104317684 @default.
• W2892187204 hasConceptScore W2892187204C121608353 @default.
• W2892187204 hasConceptScore W2892187204C126322002 @default.
• W2892187204 hasConceptScore W2892187204C143065580 @default.
• W2892187204 hasConceptScore W2892187204C143998085 @default.
• W2892187204 hasConceptScore W2892187204C170493617 @default.
• W2892187204 hasConceptScore W2892187204C185592680 @default.
• W2892187204 hasConceptScore W2892187204C2776256026 @default.
• W2892187204 hasConceptScore W2892187204C2778087573 @default.
• W2892187204 hasConceptScore W2892187204C2778820342 @default.
• W2892187204 hasConceptScore W2892187204C2779177807 @default.
• W2892187204 hasConceptScore W2892187204C2779438470 @default.
• W2892187204 hasConceptScore W2892187204C2780580887 @default.
• W2892187204 hasConceptScore W2892187204C2781230642 @default.
• W2892187204 hasConceptScore W2892187204C42362537 @default.
• W2892187204 hasConceptScore W2892187204C502942594 @default.
• W2892187204 hasConceptScore W2892187204C55493867 @default.
• W2892187204 hasConceptScore W2892187204C71924100 @default.
• W2892187204 hasConceptScore W2892187204C81729549 @default.
• W2892187204 hasLocation W28921872041 @default.
• W2892187204 hasOpenAccess W2892187204 @default.
• W2892187204 hasPrimaryLocation W28921872041 @default.
• W2892187204 hasRelatedWork W2062793335 @default.
• W2892187204 hasRelatedWork W2113451729 @default.
• W2892187204 hasRelatedWork W2261901203 @default.
• W2892187204 hasRelatedWork W2284314227 @default.
• W2892187204 hasRelatedWork W2387269381 @default.
• W2892187204 hasRelatedWork W2494484556 @default.
• W2892187204 hasRelatedWork W2588249890 @default.
• W2892187204 hasRelatedWork W2596496013 @default.
• W2892187204 hasRelatedWork W2602162531 @default.
• W2892187204 hasRelatedWork W2602652137 @default.
• W2892187204 hasRelatedWork W2613582623 @default.
• W2892187204 hasRelatedWork W2765122629 @default.
• W2892187204 hasRelatedWork W2807709930 @default.
• W2892187204 hasRelatedWork W2890048895 @default.
• W2892187204 hasRelatedWork W2922073436 @default.
• W2892187204 hasRelatedWork W2947028469 @default.
• W2892187204 hasRelatedWork W2966788232 @default.
• W2892187204 hasRelatedWork W3012119175 @default.
• W2892187204 hasRelatedWork W3031362596 @default.
• W2892187204 hasRelatedWork W3167418544 @default.
• W2892187204 isParatext "false" @default.
• W2892187204 isRetracted "false" @default.

• next